Skip to main content
ACG 2023 Annual Meeting Posters Main banner
Back
Rate ePoster

Sunday Poster Session

Category: IBD

P0726 - Cumulative Response to Guselkumab Through Week 24 of Induction in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study

Sunday, October 22, 2023
3:30 PM – 7:00 PM PT
Location: Exhibit Hall
Has Audio

    Presenting Author(s)

  • David Rubin, MD, FACG

    University of Chicago Medicine, Inflammatory Bowel Disease Center
    Chicago, IL

David T. Rubin, MD, FACG1, Bruce E. Sands, MD, MS, FACG2, Gary R. Lichtenstein, MD3, Thomas Baker, 4, Kuan-Hsiang G. Huang, MD, PhD4, Matthew Germinaro, MD4, Ye Miao, MS4, Hongyan Zhang, PhD4, Stéphane Nancey, MD, PhD5, Jessica R.. Allegretti, MD, MPH6, Brian G. Feagan, MD7, Tadakazu Hisamatsu, MD, PhD8, Julian Panés, MD, PhD9, Axel Dignass, MD, PhD10, Brian Bressler, MD, MS, FRCPC11, Laurent Peyrin-Biroulet, MD, PhD12
1University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, IL; 2Icahn School of Medicine at Mount Sinai, New York, NY; 3University of Pennsylvania, Philadelphia, PA; 4Janssen Research & Development, LLC, Spring House, PA; 5Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre-Bénite, Auvergne, France; 6Brigham and Women's Hospital, Harvard Medical School, Boston, MA; 7Western University, London, ON, Canada; 8Kyorin University School of Medicine, Tokyo, Tokyo, Japan; 9Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Catalonia, Spain; 10Agaplesion Markus Hospital, Goethe University, Frankfurt, Hessen, Germany; 11St. Paul’s Hospital, Vancouver, BC, Canada; 12Last Inserm U954 and CHU de Nancy, Lorraine University, Vandoeuvre-lès-Nancy, Lorraine, France

Introduction: The Phase 3 QUASAR induction study evaluated efficacy and safety of guselkumab (GUS), an IL-23p19 subunit antagonist, in patients (pts) with moderately to severely active UC. At Week (Wk) 12, GUS 200mg IV was more effective than placebo (PBO) in inducing clinical remission and clinical response. Pts not in clinical response at Wk12 received GUS through Wk24. Here, we report GUS cumulative efficacy and safety.

Methods: Pts with a modified Mayo score of 5-9 and a centrally reviewed Mayo endoscopy subscore ≥2 at baseline (BL) were randomized 3:2 to receive GUS 200mg IV or PBO at Wks0, 4, and 8. Pts not in clinical response at Wk12 received GUS at Wks12, 16, and 20 (GUS 200mg IV→GUS 200mg SC; PBO→GUS 200mg IV) and were evaluated at Wk24. Matching IV or SC PBO were used to maintain study blinding. Final safety assessments were conducted through Wk 32 (ie, 12 wks after last dose of GUS).

Results: The primary analysis population consisted of 701 pts. BL demographics were similar among treatment groups, and approximately 50% had a history of inadequate response/intolerance to advanced therapy (ADT-IR).



At Wk12, clinical response was achieved by a higher percentage of GUS- vs PBO-treated pts (61.5% vs 27.9%, respectively; adjusted Δ [95% CI]: 33.8% [26.9%, 40.7%]; p< 0.001; Figure). Of GUS-treated pts who were not in clinical response at Wk12 and received additional GUS treatment (GUS IV→GUS SC), 55% (66/120) achieved clinical response at Wk24. Cumulative clinical response at Wk12 or 24 was achieved by 77.2% of pts randomized to GUS at BL. Pts with and without history of ADT-IR benefitted from continued treatment with GUS SC through Wk24 (51.4% and 60.9% achieved clinical response at Wk24, respectively). Of PBO-treated pts who were not in clinical response at Wk12 and received GUS treatment (PBO IV→GUS IV), clinical response rate at Wk24 (69.7%) was similar to that at Wk12 for pts randomized to GUS at BL (61.5%). Safety findings through the final safety visit were consistent with Wk12 results; no new safety signals were identified (Table). The most frequent adverse events among GUS-treated pts (n=586) were COVID-19 (7.2%), anemia (5.1%), and worsening UC (4.6%).

Discussion: Among pts randomized to GUS IV who did not achieve clinical response at Wk12, continued treatment with GUS SC allowed 55% to achieve clinical response at Wk24. Overall, more than three-quarters of pts randomized to GUS IV achieved clinical response at Wk12 or 24. No new safety signals for GUS were identified.

Figure: Figure. Cumulative clinical response through Week 24
 IV InductionCross-overCombined
 PBO IVaGUS 200mg IVa

PBO IV → GUS 200mg IVb

GUS 200mg IV → GUS 200mg SCbAll GUSc
Safety analysis set, N280421165125586
Average duration of follow-up (weeks)12.112.313.914.615.9
Average exposure (number of administrations)2.92.92.92.83.5
Deathsd2 (0.7%)1 (0.2%)001 (0.2%)
Patients with one or more:     
    Adverse events138 (49.3%)208 (49.4%)65 (39.4%)56 (44.8%)292 (49.8%)
    Serious adverse events20 (7.1%)12 (2.9%)3 (1.8%)3 (2.4%)18 (3.1%)
    Adverse events leading to discontinuation of study agent11 (3.9%)7 (1.7%)7 (4.2%)5 (4.0%)19 (3.2%)
    Infectionse43 (15.4%)67 (15.9%)26 (15.8%)18 (14.4%)104 (17.7%)
    Serious infectionse1 (0.4%)3 (0.7%)1 (0.6%)2 (1.6%)6 (1.0%)
    Adverse events within 1 hour of infusionf1 (0.4%)6 (1.4%)1 (0.6%)3 (2.4%)10 (1.7%)

Note: Includes only pts with modified Mayo score 5-9 at induction baseline. a Includes data up to Week 12 for subjects who received treatment at Week 12. Includes all data through final safety visit (12 weeks after the last dose of study intervention) for subjects who did not receive treatment at Week 12. b Includes data from Week 12 onward. c From the first guselkumab dose onward. d All reported deaths were cardiovascular in nature and the patient in GUS arm had substantial cardiovascular risk factors. e Infections were defined as any adverse event which was coded to the MedDRA system organ class 'Infections and infestations.’ f No AEs within 1 hour of infusion were serious or resulted in treatment discontinuation.


Table: Table. Safety summary through final safety visit


Disclosures:
David T. Rubin: AbbVie – Consultant. Alike Health – Stock Options. AltruBio – Consultant, Stock Options. Aslan Pharmaceuticals – Consultant. Athos Therapeutics – Consultant. Bellatrix Pharmaceuticals – Consultant. Boehringer Ingelheim – Consultant. Bristol Myers Squibb – Consultant. Celgene – Consultant. Chronicles – Consultant. ClostraBio – Consultant. Connect BioPharma – Consultant. Cornerstones Health, Inc – Advisory Committee/Board Member. Crohn's & Colitis Foundation – Advisory Committee/Board Member. Datos Health – Stock Options. EcoR1 – Consultant. Eli Lilly – Consultant. GastroIntestinal Research Foundation – Grant/Research Support. Genentech/Roche – Consultant. Gilead Sciences – Consultant. Helmsley Charitable Trust – Grant/Research Support. Iterative Health – Consultant. Iterative Health – Stock Options. Janssen – Consultant. Kaleido Biosciences – Consultant. Pfizer – Consultant. Prometheus Biosciences – Consultant. Reistone – Consultant. Seres Therapeutics – Consultant. Syneos – Consultant. Takeda – Consultant, Grant/Research Support. Target RWE – Consultant. Trellus Health – Consultant.
Bruce Sands: AbbVie – Consultant. Abivax – Consultant, Speaker’s fees. Adiso Therapeutics – Consultant. Alimentiv – Consultant. Amgen – Consultant. Arena pharmaceuticals – Consultant. Artizan Biosciences – Consultant. Artugen Therapeutics – Consultant. AstraZeneca – Consultant. Bacainn Therapeutics – Consultant. Biora Therapeutics – Consultant. Boehringer Ingelheim – Consultant. Boston Pharmaceuticals – Consultant. Bristol Myers Squibb – Consultant, Grant/Research Support, speaking fees and other support. Calibr – Consultant. Celltrion – Consultant. ClostraBio – Consultant. Connect Biopharm – Consultant. Cytoki Pharma – Consultant. Eli Lilly – Consultant, speaking fees and other support. Enthera – Consultant. Evommune – Consultant. Ferring – Consultant. Fresenius Kabi – Consultant. Galapagos – Consultant. Genentech – Consultant. Gilead Sciences – Consultant. GlaxoSmithKline – Consultant. Gossamer Bio – Consultant. HMP Acquisition – Consultant. Imhotex – Consultant. Immunic – Consultant. InDex Pharmaceuticals – Consultant. Innovation Therapeutics – Consultant. Inotrem – Consultant. Ironwood Pharmaceuticals – Consultant. Janssen – Grant/Research Support, consulting and speaking fees and other support. Johnson & Johnson – Consultant. Kaleido Biosciences – Consultant. Kallyope – Consultant. Merck – Consultant. MiroBio – Consultant. Morphic Therapeutics – Consultant. MRM Health – Consultant. OSE Immunotherapeutics – Consultant. Pfizer Inc – Consultant, Grant/Research Support, speaking fees and other support. Progenity – Consultant. Prometheus Biosciences – Consultant. Prometheus Laboratories – Consultant. Protagonist Therapeutics – Consultant. Q32 Bio – Consultant. RedHill Biopharma – Consultant. Sun Pharma – Consultant. Surrozen – Consultant. Synlogic Operating Company – Consultant. Takeda – Grant/Research Support, consulting and speaking fees and other support. Target RWE – Consultant. Theravance Biopharma – Consultant, Grant/Research Support. TLL Pharmaceutical – Consultant. USWM Enterprises – Consultant. Ventyx Biosciences – Consultant, personal fees and stock options for consulting. Viela Bio – Consultant.
Gary R. Lichtenstein: Abbvie – Consultant. American College of Gastroenterology – Honorarium for Associate Editor of American Journal of Gastroenterology. American Gastroenterological Association – CME. American Regent – Consultant, Honorarium [CME Program]. Celgene – Consultant, Grant/Research Support. CellCeutrix – Consultant. Chemed – CME. Eli Lilly – Consultant, Data Safety Monitoring Board. Endo Pharmaceuticals – Consultant. Ferring – Consultant. Gastroenterology and Hepatology – Gastro-Hep Communication, Editor-Honorarium. Gilead – Consultant. IMEDEX – CME. Ironwood – CME. Janssen/ Janssen Orthobiotech – Consultant, Grant/Research Support, Funding to University of PA [IBD Fellow Education]. MedEd Consultants – Consultant. Merck – Consultant, Honorarium [CME Program]. Morphic Therapeutics – Consultant. Pfizer Pharmaceuticals – Consultant, Funding to University of PA [IBD Fellow Education]. Professional Communications, Inc – Royalty for writing Textbook. Prometheus Laboratories, Inc – Consultant. Romark – Consultant, Honorarium for CME. Salix Pharmaceuticals/Valeant – Consultant. Sandoz – Consultant. Shire Pharmaceuticals – Consultant. SLACK, Inc – Book Royalty. Springer Science and Business Media – Editor [Honorarium]. Takeda – Consultant, Grant/Research Support, Funding to University of PA [IBD Fellow Education]. UCB – Consultant, Grant/Research Support. University of Kentucky – CME. Up-To-Date – Author [Honorarium]. Vindico – CME. Virgo – Consultant, Stock Options.
Thomas Baker: Johnson & Johnson – Employee, Stock Options, Stock-publicly held company(excluding mutual/index funds).
Kuan-Hsiang G. Huang: Johnson & Johnson – Employee, Stock Options, Stock-publicly held company(excluding mutual/index funds).
Matthew Germinaro: Johnson & Johnson – Employee, Stock Options, Stock-publicly held company(excluding mutual/index funds).
Ye Miao: Johnson & Johnson – Employee, Stock Options, Stock-publicly held company(excluding mutual/index funds).
Hongyan Zhang: Johnson & Johnson – Employee, Stock Options, Stock-publicly held company(excluding mutual/index funds).
Stéphane Nancey: Janssen – Consultant, clinical investigator.
Jessica Allegretti: Abbvie – Consultant, Speakers Bureau. Adiso Therapeutics – Consultant. Artizan – Consultant. Artugen Therapeutics – Consultant. Baccain – Consultant. Bristol-Myers Squibb/Celgene – Consultant, Speakers Bureau. Ferring Pharmaceuticals – Consultant. Finch Therapeutics – Consultant. Iterative Scopes – Consultant. Janssen – Consultant, Grant/Research Support, Speakers Bureau. Merck – Consultant, Grant/Research Support. Morphic – Consultant. Pandion Therapeutics – Consultant. Pfizer – Consultant, Grant/Research Support. Roivant Sciences – Consultant. Seres Therapeutics – Consultant. Servatus – Consultant. Summit – Consultant.
Brian Feagan: AbbVie – Advisory Committee/Board Member, Consultant, Speakers Bureau. AbolerIS – Consultant. AgomAB Therapeutics – Consultant. Allianthera – Consultant. Amgen – Advisory Committee/Board Member, Consultant. AnaptysBio – Consultant. Applied Molecular Transport Inc. – Consultant. Arena Pharma – Consultant. Avir – Consultant. Azora Therapeutics – Consultant. Baxter – Consultant. BioJamp – Consultant. Biora Therapeutics – Consultant. Boehringer Ingelheim – Advisory Committee/Board Member, Consultant. Boston Pharma – Consultant. Bristol Myers Squibb – Consultant. Celgene/BMS – Advisory Committee/Board Member, Consultant. Connect BioPharma – Consultant. Cytoki – Consultant. Disc Medicine – Consultant. Duality – Consultant. EcoR1 – Advisory Committee/Board Member, Consultant. Eli Lilly – Consultant. Equillium – Consultant. Ermium – Consultant. Everest Clinical Research Corp. – Consultant. Ferring Pharmaceuticals – Consultant. First Wave – Consultant. Galapagos – Consultant. Galen Atlantica – Consultant. Genentech/Roche – Advisory Committee/Board Member, Consultant. Gilead – Consultant. GlaxoSmithKline – Advisory Committee/Board Member, Consultant. Glenmark – Consultant. Gossamer Pharma – Consultant, stock shareholder. Hoffmann-LaRoche – Consultant. Hot Spot Therapeutics – Consultant. Imhotex – Consultant. ImmunExt – Consultant. Immunic Therapeutics – Consultant. Index Pharma – Advisory Committee/Board Member, Consultant. Intact Therapeutics – Consultant. JAKAcademy – Consultant. Janssen – Advisory Committee/Board Member, Consultant, Speakers Bureau. Japan Tobacco Inc. – Consultant. Kaleido Biosciences – Consultant. L.E.K. Consulting – Consultant. Landos Biopharma – Consultant. Leadiant – Consultant. LifeSci Capital – Consultant. Lument AB – Consultant. Millennium – Consultant. MiroBio – Consultant. Morphic Therapeutics – Advisory Committee/Board Member, Consultant. Mylan – Consultant. Novartis – Advisory Committee/Board Member. OM Pharma – Consultant. Origo BioPharma – Advisory Committee/Board Member, Consultant. Orphagen – Consultant. Otsuka – Consultant. Pandion Therapeutics – Consultant. Pfizer – Advisory Committee/Board Member, Consultant. Play to Know AG – Consultant. Progenity – Advisory Committee/Board Member, Consultant. Prometheus Therapeutics and Diagnostics – Advisory Committee/Board Member, Consultant. Protagonist – Consultant. PTM Therapeutics – Consultant. Q32 Bio – Consultant. Rebiotix – Consultant. RedHill Biopharma – Consultant. Redx – Consultant. Roche – Consultant. Sandoz – Consultant. Sanofi – Consultant. Seres Therapeutics – Consultant. Silverback Therapeutics – Consultant. Surrozen Inc. – Consultant. Takeda – Advisory Committee/Board Member, Consultant, Speakers Bureau. Teva – Advisory Committee/Board Member, Consultant. Thelium – Consultant. Theravance – Consultant. Tigenix – Consultant. Tillotts Pharma – Advisory Committee/Board Member, Consultant. UCB Pharma – Consultant. VHSquared Ltd. – Consultant. Viatris – Consultant. Western University, Alimentiv Inc – Employee. Ysios – Consultant. Ysopia – Consultant. Zealand Pharma – Consultant.
Tadakazu Hisamatsu: AbbVie GK – Grant/Research Support, honoraria and had expenses paid to attend or give a presentation/advice at a meeting. Alfresa Pharma Corporation and EA Pharma Co., Ltd – Grant/Research Support. Daiichi-Sankyo – Grant/Research Support. EA Pharma Co, Ltd – Grant/Research Support, honoraria and had expenses paid to attend or give a presentation/advice at a meeting. Eli Lilly – Consultant. Gilead Sciences – honoraria and had expenses paid to attend or give a presentation/advice at a meeting. Janssen Pharmaceutical K.K. – honoraria and had expenses paid to attend or give a presentation/advice at a meeting. JIMRO Co., Ltd – Grant/Research Support, honoraria and had expenses paid to attend or give a presentation/advice at a meeting. KISSEI PHARMACEUTICAL CO., LTD – honoraria and had expenses paid to attend or give a presentation/advice at a meeting. Kyorin Pharmaceutical Co., Ltd – Grant/Research Support, honoraria and had expenses paid to attend or give a presentation/advice at a meeting. Mitsubishi Tanabe Pharma Corporation – Grant/Research Support, honoraria and had expenses paid to attend or give a presentation/advice at a meeting. Mochida Pharmacuetical Co., Ltd – Grant/Research Support, honoraria and had expenses paid to attend or give a presentation/advice at a meeting. Nichi-Iko Pharmaceutical Co., Ltd – honoraria and had expenses paid to attend or give a presentation/advice at a meeting. Nippon Kayaku Co., Ltd – Grant/Research Support. Pfizer Japan Inc. – Grant/Research Support, honoraria and had expenses paid to attend or give a presentation/advice at a meeting. Takeda Pharmaceutical Co., Ltd – Grant/Research Support, honoraria and had expenses paid to attend or give a presentation/advice at a meeting. Zeria Pharmaceutical Co., Ltd – Grant/Research Support.
Julian Panés: AbbVie – Grant/Research Support, Personal fees. Arena – Consultant. Athos – Consultant. Atomwise – Consultant. Boehringer Ingelheim – Consultant. Celgene – Consultant. Celltrion – Consultant. Ferring – Consultant, Speakers Bureau. Galapagos – Consultant. Genentech/Roche – Consultant. GlaxoSmithKline – Consultant. Immunic – Personal fees. Janssen – Consultant, payment for development of educational presentations. Mirum – Consultant. Morphic – Consultant. Origo – Consultant. Pandion – Consultant. Pfizer Inc – Grant/Research Support, payment for development of educational presentations. Progenity – Consultant. Revolo – Consultant. Takeda – payment for development of educational presentations. Theravance – Consultant. Wasserman – Consultant.
Axel Dignass: AbbVie – Consultant, participation in clinical trials, review activities such as data monitoring boards, statistical analysis and end point committees, Speakers Bureau. Abivax – participation in clinical trials, review activities such as data monitoring boards, statistical analysis and end point committees. Amgen – Consultant. Arena Pharmaceuticals – Consultant, participation in clinical trials, review activities such as data monitoring boards, statistical analysis and end point committees. Biogen – Consultant, Speakers Bureau. Boehringer Ingelheim – Consultant. Bristol Myers Squibb/Celgene – Consultant, participation in clinical trials, review activities such as data monitoring boards, statistical analysis and end point committees. CED Service GmbH – Speakers Bureau. Celltrion – Consultant, Speakers Bureau. Dr Falk Foundation – Consultant, participation in clinical trials, review activities and manuscript preparation, Speakers Bureau. Ferring – Consultant, Speakers Bureau. Fresenius Kabi – Consultant. Galapagos – Consultant, participation in clinical trials, review activities such as data monitoring boards, statistical analysis and end point committees, Speakers Bureau. Gilead – participation in clinical trials, review activities such as data monitoring boards, statistical analysis and end point committees, Speakers Bureau. High5MD – Speakers Bureau. Janssen – Consultant, participation in clinical trials, review activities such as data monitoring boards, statistical analysis and end point committees, Speakers Bureau. Lilly – Consultant. Materia Prima – Speakers Bureau. MedToday – Speakers Bureau. MSD – Consultant, Speakers Bureau. Pfizer – Consultant, participation in clinical trials, review activities such as data monitoring boards, statistical analysis and end point committees, Speakers Bureau. Pharmacosmos – Consultant. Roche/Genentech – Consultant. Sandoz/Hexal – Consultant. Streamed-Up – Speakers Bureau. Takeda – Consultant, manuscript preparation, Speakers Bureau. Thieme – manuscript preparation. Tillotts – Consultant, Speakers Bureau. UniMed Verlag – manuscript preparation. Vifor Pharma – Consultant, Speakers Bureau.
Brian Bressler: AbbVie – Advisory Committee/Board Member, Grant/Research Support, Speakers Bureau. Alimentiv – Advisory Committee/Board Member. Allergan – Advisory Committee/Board Member. Alvine – Grant/Research Support. Amgen – Advisory Committee/Board Member, Grant/Research Support. AMT – Advisory Committee/Board Member. Bausch Health – Advisory Committee/Board Member. Boehringer Ingelheim – Grant/Research Support. Bristol Myers Squibb – Advisory Committee/Board Member, Grant/Research Support, Speakers Bureau. Celgene – Advisory Committee/Board Member, Grant/Research Support. Ferring – Advisory Committee/Board Member, Speakers Bureau. Fresenius Kabi – Advisory Committee/Board Member. Genentech – Advisory Committee/Board Member, Grant/Research Support. Gilead – Advisory Committee/Board Member. GlaxoSmithKline – Grant/Research Support. Iterative Scopes – Advisory Committee/Board Member. Janssen – Advisory Committee/Board Member, Grant/Research Support, Speakers Bureau. Merck – Advisory Committee/Board Member, Grant/Research Support, Speakers Bureau. Microbiome Insights – Advisory Committee/Board Member. Mylan – Advisory Committee/Board Member. Novartis – Advisory Committee/Board Member, Speakers Bureau. Pendopharm – Advisory Committee/Board Member. Pfizer – Advisory Committee/Board Member, Speakers Bureau. Protagonist – Advisory Committee/Board Member. Qu Biologic – Grant/Research Support, Stock Options. Takeda – Advisory Committee/Board Member, Speakers Bureau.
Laurent Peyrin-Biroulet: AbbVie – Advisory Committee/Board Member, Consultant, Grant/Research Support, Speakers Bureau. Allergan – personal fees. Alma – personal fees. Amgen – Advisory Committee/Board Member, Consultant, Speakers Bureau. Applied Molecular Transport – personal fees. Arena – personal fees. Biogaran – Advisory Committee/Board Member, Consultant, Speakers Bureau. Biogen – Advisory Committee/Board Member, Consultant, Speakers Bureau. Boehringer Ingelheim – Advisory Committee/Board Member, Consultant, Speakers Bureau. Bristol Myers Squibb – personal fees. Celgene – Advisory Committee/Board Member, Consultant, Speakers Bureau. Celltrion – Advisory Committee/Board Member, Consultant, Speakers Bureau. CTMA – Stock Options. Eli Lilly – Advisory Committee/Board Member, Consultant, Speakers Bureau. Enterome – personal fees. Enthera – personal fees. Ferring – Advisory Committee/Board Member, Consultant, Speakers Bureau. Forward Pharma – Advisory Committee/Board Member, Consultant, Speakers Bureau. Fresenius – personal fees. Genentech – Advisory Committee/Board Member, Consultant, Speakers Bureau. Gilead – personal fees. H.A.C. Pharma – Advisory Committee/Board Member, Consultant, Speakers Bureau. Hikma – personal fees. Hospira/Pfizer – Advisory Committee/Board Member, Consultant, Speakers Bureau. Index Pharmaceuticals – Advisory Committee/Board Member, Consultant, Speakers Bureau. Janssen – Advisory Committee/Board Member, Consultant, Speakers Bureau. Lycera – Advisory Committee/Board Member, Consultant, Speakers Bureau. Merck – Advisory Committee/Board Member, Consultant, Speakers Bureau. Mitsubishi – Advisory Committee/Board Member, Consultant, Speakers Bureau. MSD – Grant/Research Support, personal fees. Mylan – personal fees. Nestlé – personal fees. Norgine – Advisory Committee/Board Member, Consultant, Speakers Bureau. Oppilan Pharma – personal fees. OSE Immunotherapeutics – personal fees. Pfizer – personal fees. Pharmacosmos – personal fees. Roche – personal fees. Samsung Bioepis – Advisory Committee/Board Member, Consultant, Speakers Bureau. Sandoz – Advisory Committee/Board Member, Consultant, Speakers Bureau. Sterna – personal fees. Sublimity Therapeutics – personal fees. Takeda – Advisory Committee/Board Member, Consultant, Speakers Bureau. Theravance – Advisory Committee/Board Member, Consultant, Speakers Bureau. Tillots – Advisory Committee/Board Member, Consultant, Speakers Bureau. Vifor – Advisory Committee/Board Member, Consultant, Speakers Bureau.


David T. Rubin, MD, FACG1, Bruce E. Sands, MD, MS, FACG2, Gary R. Lichtenstein, MD3, Thomas Baker, 4, Kuan-Hsiang G. Huang, MD, PhD4, Matthew Germinaro, MD4, Ye Miao, MS4, Hongyan Zhang, PhD4, Stéphane Nancey, MD, PhD5, Jessica R.. Allegretti, MD, MPH6, Brian G. Feagan, MD7, Tadakazu Hisamatsu, MD, PhD8, Julian Panés, MD, PhD9, Axel Dignass, MD, PhD10, Brian Bressler, MD, MS, FRCPC11, Laurent Peyrin-Biroulet, MD, PhD12. P0726 - Cumulative Response to Guselkumab Through Week 24 of Induction in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study, ACG 2023 Annual Scientific Meeting Abstracts. Vancouver, BC, Canada: American College of Gastroenterology.